AAAAAA

   
Results: 1-24 |
Results: 24
DETERMINATION OF RISK-FACTORS THAT AFFECT ENGRAFTMENT AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: ELFENBEIN G PARTYKA J SAEZ R GOLDSTEIN S FIELDS K PERKINS J JANSSEN W
Citation: G. Elfenbein et al., DETERMINATION OF RISK-FACTORS THAT AFFECT ENGRAFTMENT AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Experimental hematology, 26(8), 1998, pp. 37-37
MULTIVARIATE-ANALYSIS OF PRE-AND POSTTRANSPLANT FACTORS RELATED TO OUTCOME IN 65 CONSECUTIVE ALLOGENEIC TRANSPLANT PATIENTS (ALLO-BMT) RECEIVING CYCLOSPORINE METHOTREXATE (CSA/MTX) AS GRAFT-VS-HOST-DISEASE (GVHD) PROPHYLAXIS/
Authors: SAEZ R PERKINS J GOLDSTEIN S KRONISH L ELFENBEIN G PARTYKA J BALLESTER O SULLIVAN D FIELDS K
Citation: R. Saez et al., MULTIVARIATE-ANALYSIS OF PRE-AND POSTTRANSPLANT FACTORS RELATED TO OUTCOME IN 65 CONSECUTIVE ALLOGENEIC TRANSPLANT PATIENTS (ALLO-BMT) RECEIVING CYCLOSPORINE METHOTREXATE (CSA/MTX) AS GRAFT-VS-HOST-DISEASE (GVHD) PROPHYLAXIS/, Experimental hematology, 25(8), 1997, pp. 322-322
COMPARISON OF THE TOXICITY PROFILES OF BUSULFAN CYTOXAN (BUCY2) CONDITIONING REGIMENS WITH AND WITHOUT ETOPOSIDE IN PATIENTS WITH LYMPHOMA/
Authors: GOLDSTEIN S KRONISH L PARTYKA J SAEZ R SULLIVAN D ELFENBEIN G JANSSEN W FIELDS K
Citation: S. Goldstein et al., COMPARISON OF THE TOXICITY PROFILES OF BUSULFAN CYTOXAN (BUCY2) CONDITIONING REGIMENS WITH AND WITHOUT ETOPOSIDE IN PATIENTS WITH LYMPHOMA/, Blood, 90(10), 1997, pp. 4366-4366
OBSTACLES TO PERFORMING HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD STEM-CELL RESCUE (HDT PBSCR) IN THE OUTPATIENT SETTING/
Authors: SHARMA N HENDRIX L OCONNELL M FIELDS K SULLIVAN D SAEZ R ELFENBEIN G GOLDSTEIN S
Citation: N. Sharma et al., OBSTACLES TO PERFORMING HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD STEM-CELL RESCUE (HDT PBSCR) IN THE OUTPATIENT SETTING/, Blood, 90(10), 1997, pp. 504-504
TO THE EDITOR
Authors: BENSON K ELFENBEIN G
Citation: K. Benson et G. Elfenbein, TO THE EDITOR, American journal of clinical pathology, 107(2), 1997, pp. 251-251
VARIABILITY IN ENGRAFTMENT POTENTIAL OF DIFFERENT PERIPHERAL-BLOOD STEM-CELL PREPARATIONS GIVEN AFTER CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN FOR STAGE II III BREAST-CANCER/
Authors: ELFENBEIN G PERKINS J JANSSEN W FIELDS K
Citation: G. Elfenbein et al., VARIABILITY IN ENGRAFTMENT POTENTIAL OF DIFFERENT PERIPHERAL-BLOOD STEM-CELL PREPARATIONS GIVEN AFTER CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN FOR STAGE II III BREAST-CANCER/, Experimental hematology, 24(9), 1996, pp. 107-107
THROMBOCYTOPENIA AS A COMPLICATION OF HIGH-DOSE G-CSF USED TO MOBILIZE PERIPHERAL-BLOOD STEM-CELLS
Authors: TUMMALA R ELFENBEIN G FIELD K PERKINS J PARTYKA J KRONISH L
Citation: R. Tummala et al., THROMBOCYTOPENIA AS A COMPLICATION OF HIGH-DOSE G-CSF USED TO MOBILIZE PERIPHERAL-BLOOD STEM-CELLS, Experimental hematology, 24(9), 1996, pp. 430-430
INTERLEUKIN-3 IS EFFECTIVE FOR ENGRAFTMENT FAILURE FOLLOWING HIGH-DOSE THERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION
Authors: BALLESTER O SULLIVAN P HENDRIX L PERKINS J HIEMENZ J FIELDS K GOLDSTEIN S SULLIVAN D ELFENBEIN G
Citation: O. Ballester et al., INTERLEUKIN-3 IS EFFECTIVE FOR ENGRAFTMENT FAILURE FOLLOWING HIGH-DOSE THERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION, Experimental hematology, 24(9), 1996, pp. 431-431
HIGH-DOSE THERAPY WITH AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE-MYELOMA AND RENAL-FAILURE
Authors: TUMMALA R BALLESTER O JANSSEN W FIELDS K HIEMENZ J GOLDSTEIN S PERKINS J ROSEN R SAEZ R ELFENBEIN G
Citation: R. Tummala et al., HIGH-DOSE THERAPY WITH AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE-MYELOMA AND RENAL-FAILURE, Experimental hematology, 24(9), 1996, pp. 706-706
PHASE I II TRIAL OF HIGH-DOSE IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE (ICE) AT MAXIMUM TOLERATED DOSAGE (MTD) WITH AUTOLOGOUS STEM-CELL RESCUE FOR REFRACTORY LYMPHOMA/
Authors: GOLDSTEIN S KRONISH L BALLESTER O HIEMENZ J SULLIVAN D SAEZ R SACKSTEIN R PARTYKA J PERKINS J JANSSEN W ELFENBEIN G FIELDS K
Citation: S. Goldstein et al., PHASE I II TRIAL OF HIGH-DOSE IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE (ICE) AT MAXIMUM TOLERATED DOSAGE (MTD) WITH AUTOLOGOUS STEM-CELL RESCUE FOR REFRACTORY LYMPHOMA/, Blood, 88(10), 1996, pp. 486-486
MANAGEMENT OF DIALYSIS DEPENDENT MULTIPLE-MYELOMA PATIENTS DURING AUTOLOGOUS BONE-MARROW TRANSPLANTATION
Authors: ROSEN R PEREZ E WAHE M RAMIREZ G BALLESTER O ELFENBEIN G
Citation: R. Rosen et al., MANAGEMENT OF DIALYSIS DEPENDENT MULTIPLE-MYELOMA PATIENTS DURING AUTOLOGOUS BONE-MARROW TRANSPLANTATION, Journal of the American Society of Nephrology, 6(3), 1995, pp. 401-401
IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: MOREB J JOHNSON T KUBILIS P MYERS L OBLON D MILLER A ELFENBEIN G WEINER R
Citation: J. Moreb et al., IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION, American journal of hematology, 50(4), 1995, pp. 304-306
THE WBC RECOVERY RATE AFTER PRIMING WITH CYVP16-BLOOD STEM-CELL RESCUE(GCSF IS A DETERMINANT OF ANC RECOVERY AND SURVIVAL AFTER BUCY2 AND AUTOLOGOUS PERIPHERAL)
Authors: ZORSKY P FANG T JANSSEN W BALLESTER O FIELDS K GOLDSTEIN S HIEMENZ J ELFENBEIN G
Citation: P. Zorsky et al., THE WBC RECOVERY RATE AFTER PRIMING WITH CYVP16-BLOOD STEM-CELL RESCUE(GCSF IS A DETERMINANT OF ANC RECOVERY AND SURVIVAL AFTER BUCY2 AND AUTOLOGOUS PERIPHERAL), Blood, 86(10), 1995, pp. 391-391
HIGH-DOSE THERAPY WITH AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE-MYELOMA AND END-STAGE RENAL-FAILURE
Authors: BALLESTER O ZORSKY P JANSSEN W FIELDS K HIEMENZ J GOLDSTEIN S PERKINS J ROSEN R ELFENBEIN G
Citation: O. Ballester et al., HIGH-DOSE THERAPY WITH AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE-MYELOMA AND END-STAGE RENAL-FAILURE, Blood, 86(10), 1995, pp. 811-811
COMPARISON OF CYCLOSPORINE (CSA) PLUS METHYLPREDNISOLONE (MEPRED) VS CSA PLUS METHOTREXATE (MTX) FOR GVHD PROPHYLAXIS IN HLA IDENTICAL ALLOGENIC BONE-MARROW TRANSPLANTATION (BMT)
Authors: ZORSKY P BALLESTER O GOLDSTEIN S HIEMENZ J JANSSEN W FIELDS K ELFENBEIN G
Citation: P. Zorsky et al., COMPARISON OF CYCLOSPORINE (CSA) PLUS METHYLPREDNISOLONE (MEPRED) VS CSA PLUS METHOTREXATE (MTX) FOR GVHD PROPHYLAXIS IN HLA IDENTICAL ALLOGENIC BONE-MARROW TRANSPLANTATION (BMT), Blood, 86(10), 1995, pp. 1573-1573
HEMATOLOGIC PARAMETERS OBTAINED BEFORE STEM-CELL PRIMING WITH CYVP-BLOOD STEM-CELL RESCUE (ASCR)(GCSF PREDICT OUTCOME AFTER BUCY2 PLUS AUTOLOGOUS PERIPHERAL)
Authors: FANG T ZORSKY T JANSSEN W HIEMENZ J BALLESTER O FIELDS K GOLDSTEIN S ELFENBEIN G
Citation: T. Fang et al., HEMATOLOGIC PARAMETERS OBTAINED BEFORE STEM-CELL PRIMING WITH CYVP-BLOOD STEM-CELL RESCUE (ASCR)(GCSF PREDICT OUTCOME AFTER BUCY2 PLUS AUTOLOGOUS PERIPHERAL), Blood, 86(10), 1995, pp. 3766-3766
SYNERGY BETWEEN BONE-MARROW (BM) CELLS AND PERIPHERAL-BLOOD STEM-CELLS (PBSC) IN THE ABILITY TO FORM GRANULOCYTE MONOCYTE COLONY-FORMING-UNITS (CFU-GM) IN-VITRO/
Authors: SHIVERS SC CARTER R ELFENBEIN G JANSSEN WE
Citation: Sc. Shivers et al., SYNERGY BETWEEN BONE-MARROW (BM) CELLS AND PERIPHERAL-BLOOD STEM-CELLS (PBSC) IN THE ABILITY TO FORM GRANULOCYTE MONOCYTE COLONY-FORMING-UNITS (CFU-GM) IN-VITRO/, Experimental hematology, 22(8), 1994, pp. 758-758
PHASE-I CONCENTRATION-CONTROLLED, ESCALATION TRIAL OF LISOFYLLINE (LSF) IN PATIENTS (PTS) UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION(BMT)
Authors: LIST A SHUSTER M BLAZAR B ELFENBEIN G NEMUNAITIS J FLOMENBERG N KURTZBERG J BAKKE L THOELKE K SINGER JW BIANCO JA
Citation: A. List et al., PHASE-I CONCENTRATION-CONTROLLED, ESCALATION TRIAL OF LISOFYLLINE (LSF) IN PATIENTS (PTS) UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION(BMT), Blood, 84(10), 1994, pp. 10000089-10000089
DEMONSTRATION OF SPECIFIC LYMPHOCYTE-ENDOTHELIAL CELL-ADHESION IN CUTANEOUS GRAFT-VERSUS-HOST DISEASE
Authors: SACKSTEIN R MESSINA J ELFENBEIN G
Citation: R. Sackstein et al., DEMONSTRATION OF SPECIFIC LYMPHOCYTE-ENDOTHELIAL CELL-ADHESION IN CUTANEOUS GRAFT-VERSUS-HOST DISEASE, Blood, 84(10), 1994, pp. 10000100-10000100
CHEMOMOBILIZATION OF BCR ABL-NEGATIVE PERIPHERAL-BLOOD STEM-CELLS FORAUTOLOGOUS TRANSPLANTATION IN CHRONIC MYELOGENOUS LEUKEMIA/
Authors: GOLDSTEIN S ALKAN S JANSSEN W THOMPSON J MOSCINSKI L BALLESTER O HIEMENZ J ZORSKY P PERKINS J FIELDS K ELFENBEIN G
Citation: S. Goldstein et al., CHEMOMOBILIZATION OF BCR ABL-NEGATIVE PERIPHERAL-BLOOD STEM-CELLS FORAUTOLOGOUS TRANSPLANTATION IN CHRONIC MYELOGENOUS LEUKEMIA/, Blood, 84(10), 1994, pp. 10000710-10000710
THE PLATELET-REFRACTORY BONE-MARROW TRANSPLANT PATIENT - PROPHYLAXIS AND TREATMENT OF BLEEDING
Authors: BENSON K FIELDS K HIEMENZ J ZORSKY P BALLESTER O PERKINS J ELFENBEIN G
Citation: K. Benson et al., THE PLATELET-REFRACTORY BONE-MARROW TRANSPLANT PATIENT - PROPHYLAXIS AND TREATMENT OF BLEEDING, Seminars in oncology, 20(5), 1993, pp. 102-109
PHASE-III DOUBLE-BLIND TRIAL OF RHGM-CSF (SARGRAMOSTIN) FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANT (BMT)
Authors: NEMUNAITIS J ROSENFELD C ASH R FLOMENBERG N FRIEDMAN M DEEG J APPELBAUM F SINGER JW DALTON W ELFENBEIN G RIFKIN R RUBIN A AGOSTI J HAYES FA SHADDUCK RK
Citation: J. Nemunaitis et al., PHASE-III DOUBLE-BLIND TRIAL OF RHGM-CSF (SARGRAMOSTIN) FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANT (BMT), Blood, 82(10), 1993, pp. 10000286-10000286
SUCCESSFUL HLA-MATCHED RELATED ALLOGENEIC BONE-MARROW (BM) ENGRAFTMENT WITH CADAVERIC DONOR CELLS
Authors: AGALIOTIS D HIEMENZ J JANSSEN W FIELDS K ZORSKY P BALLESTER O ELFENBEIN G
Citation: D. Agaliotis et al., SUCCESSFUL HLA-MATCHED RELATED ALLOGENEIC BONE-MARROW (BM) ENGRAFTMENT WITH CADAVERIC DONOR CELLS, Blood, 82(10), 1993, pp. 10000626-10000626
RAPID ENGRAFTMENT FOLLOWING BUSULFAN CYCLOPHOSPHAMIDE AND AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION FOR HIGH-RISK HEMATOLOGICAL MALIGNANCIES
Authors: BALLESTER O JANSSEN W ELFENBEIN G FIELDS K HIEMENZ J ZORSKY P KRONISH L BEACH B FOODY M SHERMAN M
Citation: O. Ballester et al., RAPID ENGRAFTMENT FOLLOWING BUSULFAN CYCLOPHOSPHAMIDE AND AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION FOR HIGH-RISK HEMATOLOGICAL MALIGNANCIES, Blood, 82(10), 1993, pp. 10000626-10000626
Risultati: 1-24 |